Shares of Cytosorbents Corporation (NASDAQ:CTSO) have been given an average rating of “Buy” by the six research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $10.45.
Several research firms have commented on CTSO. B. Riley reissued a “buy” rating and set a $11.25 target price on shares of Cytosorbents Corporation in a research report on Monday, August 7th. Maxim Group lifted their target price on shares of Cytosorbents Corporation from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, August 8th. HC Wainwright set a $13.00 target price on shares of Cytosorbents Corporation and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Aegis reissued a “buy” rating and set a $9.00 target price on shares of Cytosorbents Corporation in a research report on Tuesday, July 25th. Finally, ValuEngine cut shares of Cytosorbents Corporation from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd.
Several large investors have recently bought and sold shares of CTSO. Sabby Management LLC bought a new stake in shares of Cytosorbents Corporation in the 1st quarter worth approximately $990,000. Skylands Capital LLC raised its holdings in shares of Cytosorbents Corporation by 87.7% in the 2nd quarter. Skylands Capital LLC now owns 594,250 shares of the medical research company’s stock worth $2,555,000 after purchasing an additional 277,650 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Cytosorbents Corporation by 145.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after purchasing an additional 22,500 shares during the period. 6.89% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/26/cytosorbents-corporation-ctso-given-consensus-rating-of-buy-by-analysts.html.
Cytosorbents Corporation (NASDAQ:CTSO) traded down 1.63% during mid-day trading on Thursday, reaching $6.05. The company’s stock had a trading volume of 98,119 shares. The company’s market cap is $170.20 million. The firm has a 50 day moving average price of $5.78 and a 200 day moving average price of $4.85. Cytosorbents Corporation has a 52-week low of $3.30 and a 52-week high of $6.70.
Cytosorbents Corporation (NASDAQ:CTSO) last posted its earnings results on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. Cytosorbents Corporation had a negative net margin of 80.56% and a negative return on equity of 529.95%. The firm had revenue of $3.57 million for the quarter, compared to analysts’ expectations of $3.29 million. Equities research analysts anticipate that Cytosorbents Corporation will post ($0.27) earnings per share for the current year.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.